Suggested remit - To appraise the clinical and cost effectiveness of ixekizumab within it marketing authorisation for treating axial spondyloarthritis
 
Status In progress
Process STA 2018
ID number 1532

Project Team

Project lead Jeremy Powell

Email enquiries

Consultees

Companies sponsors Eli Lilly

Timeline

Key events during the development of the guidance:

Date Update
08 November 2019 Invitation to participate
08 November 2019 In progress
31 January 2019 - 28 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance